Shareholder approval removes a key condition for the Angelini Pharma acquisition. The stock should trade near the $31.50 offer price as regulatory approvals are pursued. Monitor for closing timeline and any regulatory hurdles.
CPRX drugs
CPRX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Jul 9 $31.47entry
- T+1 · 4mo ago 0.00%α −0.43% · $31.47
- T+5 · 4mo ago +0.06%α +0.20% · $31.49
- T+20 · due 3mo ago Pending
- T+60 · due 7w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Catalyst Pharmaceuticals stockholders approved the $31.50/share all-cash acquisition by Angelini Pharma at the July 8, 2026 special meeting, with over 79% of outstanding shares voting in favor. The compensation proposal for executives was rejected on a non-binding advisory basis, but this does not affect deal closure. All directors have indicated their intent to resign effective at merger closing. The merger now has cleared its key stockholder condition.
Key Facts
- Merger proposal approved by holders of 97,340,180 shares For (79.5% of outstanding) vs. 1,143,815 Against and 242,616 Abstentions.
- Advisory compensation proposal NOT approved (30,504,686 For, 67,486,884 Against) but non-binding and not a condition to closing.
- All seven directors intend to resign effective at merger closing; no disagreements cited.
- 80.6% of outstanding shares were present or represented at the special meeting.
Financial Impact
All-cash acquisition at $31.50/share; total deal value not disclosed in this filing but implied by market cap of $3.9B.
Risk Factors
- Regulatory approvals or antitrust clearance may delay or block the merger.
- Shareholder lawsuit related to proxy disclosures remains outstanding (per prior DEFA14A).
- Merger termination rights under the agreement if closing conditions not met by outside date.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (CPRX), Batch item 1 | 0001193125-26-298739 |
| Document: 0001193125-26-298739-index-headers.html | 0001193125-26-298739 |
| Document: 0001193125-26-298739-index.html | 0001193125-26-298739 |
| Document: 0001193125-26-298739.txt | 0001193125-26-298739 |
| 8-K Filing (CPRX), Batch item 5 | 0001193125-26-298739 |
| Document: 0001193125-26-298739-index-headers.html | 0001193125-26-298739 |
| Document: 0001193125-26-298739-index.html | 0001193125-26-298739 |
| Document: 0001193125-26-298739.txt | 0001193125-26-298739 |
Track record
16 reports on CPRX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
- Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
- Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
- Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
- Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
- Jul 8, 202618w ago 8-K Bullish 6/10 Viewing Entry $31.47 No price data
- Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
- Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
- May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
- May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers